UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 162

Sortiert nach

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia

Blood, 2016-09, Vol.128 (10), p.1382-1395

2016

Link zum Volltext

Verfügbarkeit prüfen

Initial testing (stage 1) of tazemetostat (EPZ‐6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program

Pediatric blood & cancer, 2017-03, Vol.64 (3), p.np-n/a

2017

Link zum Volltext

Verfügbarkeit prüfen

Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer

Nature communications, 2023-11, Vol.14 (1), p.7600-7600, Article 7600

2023

Link zum Volltext

Verfügbarkeit prüfen

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report

Pediatric blood & cancer, 2020-05, Vol.67 (5), p.e28098-n/a

2020

Link zum Volltext

Verfügbarkeit prüfen

Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia

Clinical cancer research, 2015-03, Vol.21 (6), p.1395-1405

2015

Link zum Volltext

Verfügbarkeit prüfen

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Pediatric blood & cancer, 2013-08, Vol.60 (8), p.1325-1332

2013

Link zum Volltext

Verfügbarkeit prüfen

Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2

Molecular cancer therapeutics, 2012-03, Vol.11 (3), p.649-659

2012

Link zum Volltext

Verfügbarkeit prüfen

PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair

Journal of hematology and oncology, 2022-10, Vol.15 (1), p.1-6, Article 146

2022

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

Molecular cancer therapeutics, 2015-02, Vol.14 (2), p.364-374

2015

Link zum Volltext

Verfügbarkeit prüfen

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program

Pediatric blood & cancer, 2014-10, Vol.61 (10), p.1816-1821

2014

Link zum Volltext

Verfügbarkeit prüfen

Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing

Journal of clinical medicine, 2021-04, Vol.10 (7), p.1504

2021

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma

Pediatric blood & cancer, 2015-08, Vol.62 (8), p.1345-1352

2015

Link zum Volltext

Verfügbarkeit prüfen

PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma

iScience, 2022-02, Vol.25 (2), p.103725-103725, Article 103725

2022

Link zum Volltext

Verfügbarkeit prüfen

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

Pediatric blood & cancer, 2014-02, Vol.61 (2), p.245-252

2014

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive characterization of patient-derived xenograft models of pediatric leukemia

iScience, 2023-11, Vol.26 (11), p.108171-108171, Article 108171

2023

Link zum Volltext

Verfügbarkeit prüfen

Challenges and Opportunities for Childhood Cancer Drug Development

Pharmacological reviews, 2019-10, Vol.71 (4), p.671-697

2019

Link zum Volltext

Verfügbarkeit prüfen

Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors

Molecular cancer therapeutics, 2007-05, Vol.6 (5), p.1620-1628

2007

Link zum Volltext

Verfügbarkeit prüfen

Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program

Pediatric blood & cancer, 2012-09, Vol.59 (3), p.518-524

2012

Link zum Volltext

Verfügbarkeit prüfen

In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models—A report from the Pediatric Preclinical Testing Consortium

Pediatric blood & cancer, 2021-02, Vol.68 (2), p.e28772-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

The Insulin-like Growth Factor-1 Receptor―Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma

Cancer research (Chicago, Ill.), 2009-10, Vol.69 (19), p.7662-7671

2009

Link zum Volltext

Verfügbarkeit prüfen

In vivo evaluation of the lysine‐specific demethylase (KDM1A/LSD1) inhibitor SP‐2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)

Pediatric blood & cancer, 2021-11, Vol.68 (11), p.e29304-n/a

2021

Link zum Volltext

Verfügbarkeit prüfen

IGF-I mediated survival pathways in normal and malignant cells

Biochimica et biophysica acta, 2006-08, Vol.1766 (1), p.1-22

2006

Link zum Volltext

Verfügbarkeit prüfen

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program

Clinical cancer research, 2015-02, Vol.21 (4), p.819-832

2015

Link zum Volltext

Verfügbarkeit prüfen

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

Pediatric blood & cancer, 2013-05, Vol.60 (5), p.783-790

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 162

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(159)
Mit Volltextzugriff
(157)

Publikationsform

Artikel
(160)
Buchkapitel
(2)

Sprache

Englisch
(162)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(84)
Life Sciences & Biomedicine
(82)
Oncology
(78)
Humans
(74)
Animals
(71)
Mice
(60)
Xenograft Model Antitumor Assays
(53)
Pediatrics
(52)
Hematology
(48)
Female
(44)
Cell Line, Tumor
(41)
Mice, Scid
(37)
Child
(34)
Preclinical Testing
(33)
Developmental Therapeutics
(31)
Antineoplastic Agents - Pharmacology
(21)
Xenografts
(17)
Neoplasms - Drug Therapy
(15)
Neoplasms, Experimental - Drug Therapy
(15)
Tumors
(15)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia

Initial testing (stage 1) of tazemetostat (EPZ‐6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

Genomic profiling of subcutaneous patient-derived xenografts reveals immune constraints on tumor evolution in childhood solid cancer

Preclinical evaluation of the combination of AZD1775 and irinotecan against selected pediatric solid tumors: A Pediatric Preclinical Testing Consortium report

Effective targeting of the P53-MDM2 axis in preclinical models of infant MLL-rearranged acute lymphoblastic leukemia

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2

PARP1-MGMT complex underpins pathway crosstalk in O6-methylguanine repair

Evaluation of the in vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute lymphoblastic leukemia

Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program

Developing New Agents for Treatment of Childhood Cancer: Challenges and Opportunities for Preclinical Testing

Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma

PEGylated talazoparib enhances therapeutic window of its combination with temozolomide in Ewing sarcoma

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ-26481585), by the Pediatric Preclinical Testing Program

Comprehensive characterization of patient-derived xenograft models of pediatric leukemia

Challenges and Opportunities for Childhood Cancer Drug Development

Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors

Testing of the Akt/PKB inhibitor MK-2206 by the pediatric preclinical testing program

In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models—A report from the Pediatric Preclinical Testing Consortium

The Insulin-like Growth Factor-1 Receptor―Targeting Antibody, CP-751,871, Suppresses Tumor-Derived VEGF and Synergizes with Rapamycin in Models of Childhood Sarcoma

In vivo evaluation of the lysine‐specific demethylase (KDM1A/LSD1) inhibitor SP‐2577 (Seclidemstat) against pediatric sarcoma preclinical models: A report from the Pediatric Preclinical Testing Consortium (PPTC)

IGF-I mediated survival pathways in normal and malignant cells

Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

Suchergebnisse filtern